524

Статья посвящена жизненно важной проблеме  1го века - ожирению. Оно может привести к серьезным патологиям. Это можно объяснить резистенцией к инсулину и лептину. Диабет и ожирение являются двумя метаболическими заболеваниями, характеризующимися резистентностью к инсулину и слабым воспалением. 

  • Read count405
  • Date of publication29-01-2021
  • Main LanguageRus
  • Pages148-151
Русский

Статья посвящена жизненно важной проблеме  1го века - ожирению. Оно может привести к серьезным патологиям. Это можно объяснить резистенцией к инсулину и лептину. Диабет и ожирение являются двумя метаболическими заболеваниями, характеризующимися резистентностью к инсулину и слабым воспалением. 

English

Abstract: this article is focused on one of the vital problems of the 21st century- obesity. It can lead to very serious pathologies. This can also be explained by insulin and leptin resistance. Diabetes and obesity are two metabolic diseases characterized by insulin resistance and a low-grade inflammation.

Ўзбек

Ushbu maqolada XXI asrning dolzarb mavzusi yuzasida so’z yuritilgan. Semizlik jiddiy kasalliklarni keltirib chiqaradi. Buni insulin va leptinga rezistentlik bilan tushuntirish mumkin. Diabet va semizlik insulin qarshiligi va past darajadagi yallig'lanish bilan tavsiflanadigan metabolik kasalliklardir.   

№ Name of reference
1 1. Myers, M.G., Jr, Munzberg, H., Leinninger, G.M. and Leshan, R.L. et al. (2009) The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 9, 117–123
2 2. Schwartz, M.W., Woods, S.C., Porte, D., Jr, Seeley, R.J. and Baskin, D.G. et al. (2000) Central nervous system control of food intake. Nature 404, 661–671
3 3. Rosenbaum, M. and Leibel, R.L. et al. (1999) The role of leptin in human physiology. N. Engl. J. Med. 341, 913–915
4 4. Ahima, R.S., Saper, C.B., Flier, J.S. and Elmquist, J.K. et al. (2000) Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 21, 263–307
5 5. Halaas, J.L., Gajiwala, K.S. and Maffei, M. et al. (1995) Weightreducing effects of the plasma protein encoded by the obese gene. Science 269, 543–546
6 6. Chehab, F.F., Lim, M.E. and Lu, R. et al. (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics 12, 318–320
7 7. Farooqi, I.S., Jebb, S.A. and Langmack, G. et al. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency.N. Engl. J. Med. 341, 879–884
8 8. Oral, E.A., Simha, V. and Ruiz, E. et al. (2002) Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578
9 9. Shimomura, I., Hammer, R.E., Ikemoto, S., Brown, M.S. and Goldstein, J.L. et al. (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy]. Nature 401, 73–76
10 10. Chan, J.L., Heist, K., Depaoli, A.M., Veldhuis, J.D. and Mantzoros, C.S. et al. (2003) The role of falling leptin levels in the neuroendocrine Review Trends in Endocrinology and Metabolism Vol.21 No.11 649 and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 111, 1409–1421
11 11. Welt, C.K., Chan, J.L. and Bullen, J. et al. (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med. 351, 987–997
12 12. Rosenbaum, M., Murphy, E.M., Heymsfield, S.B., Matthews, D.E. and Leibel, R.L. et al. (2002) Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J. Clin. Endocrinol. Metab. 87, 2391–2394
13 14. Kaiyala, K.J., Morton, G.J., Leroux, B.G., Ogimoto, K., Wisse, B. and Schwartz, M.W. et al. (2010) Identification of body fat mass as a major determinant of metabolic rate in mice. Diabetes 59, 1657–1666
14 15. Bluher, S. and Mantzoros, C.S. et al. (2009) Leptin in humans: lessons from translational research. Am. J. Clin. Nutr. 89, 991S–997S
15 16. Ravussin, E., Smith, S.R. and Mitchell, J.A. et al. (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 17, 1736–1743
16 17. Oral, E.A. and Chan, J.L. et al. (2010) Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr. Pract. 16, 324–333
17 18. Considine, R.V., Sinha, M.K. and Heiman, M.L. et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292–295
18 19. Rosenbaum, M., Nicolson, M. and Hirsch, J. et al. (1996) Effects of gender, body composition, and menopause on plasma concentrations of leptin. J. Clin. Endocrinol. Metab. 81, 3424–3427
19 20. Frederich, R.C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B.B. and Flier, J.S. et al. (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1, 1311–1314
20 21. Myers, M. G., Leibel, R. L., Seeley, R. J., & Schwartz, M. W. (2010). Obesity and leptin resistance: distinguishing cause from effect. Trends in Endocrinology & Metabolism, 21(11), 643–651.doi:10.1016/j.tem.2010.08.002
21 22. Gong, Y., Ishida-Takahashi, R., Villanueva, E.C., Fingar, D.C., Munzberg, H. and Myers, M.G., Jr et al. (2007) The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J. Biol. Chem. 282, 31019–31027
22 23. Wang, T.-N., Chang, W.-T., Chiu, Y.-W., Lee, C.-Y., Lin, K.-D., Cheng, Y.Y, Huang, M.C. (2013). Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss. The Kaohsiung Journal of Medical Sciences, 29(8), 436– 443. doi:10.1016/j.kjms.2012.08.041
Waiting